# Ameliorating Seizures in Dravet Syndrome: A Review of Newly Approved and Investigational Drugs, RNA and Gene-Based Therapies. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ameliorating-seizures-dravet-syndrome-new-therapies-review/ > **Published:** 2026-03-26T09:00:42-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:38:08-04:00 > **Clinical Summary:** Explore emerging therapies for ameliorating seizures in Dravet syndrome, including cannabinoid and gene-based treatments with promising clinical evidence. --- CED Clinical Relevance  #60Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic [Pediatric Epilepsy](https://cedclinic.com/credit-rating-stability-pharmaceutical-cannabis/)Cbd[Dravet Syndrome](https://cedclinic.com/cannabidiol-for-epilepsy-treatment-rare-forms/)CannabinoidsSeizures Journal CNS drugs Study Type [Clinical Study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) Population Human participants Why This Matters [Dravet syndrome](https://cedclinic.com/cannabidiol-for-epilepsy-treatment-rare-forms/) represents one of the most severe pediatric epilepsies with limited treatment options and high mortality risk. This review addresses critical gaps in therapeutic approaches for a condition where conventional antiepileptics often fail and cannabinoids like CBD have shown promise. Clinical Summary This comprehensive review examines emerging therapeutic strategies for Dravet syndrome, a devastating childhood epilepsy caused primarily by SCN1A gene mutations affecting sodium channels. The authors evaluate newly approved medications, investigational compounds, and novel RNA/gene-based therapies beyond traditional antiepileptics. The review provides crucial context for understanding why standard seizure medications often worsen Dravet syndrome and how targeted approaches, including cannabinoid therapies, may offer better outcomes. Limitations include the early-stage nature of many investigated therapies and limited long-term safety data. Dr. Caplan’s Take “This reinforces why I’ve seen CBD-based treatments like Epidiolex become cornerstone therapy in my Dravet patients – the sodium channel dysfunction makes traditional approaches counterproductive. The review validates our clinical observation that mechanism-specific treatments yield better seizure control than broad-spectrum antiepileptics.” Clinical Perspective 🧠 Clinicians treating [pediatric epilepsy](https://cedclinic.com/credit-rating-stability-pharmaceutical-cannabis/) should recognize Dravet syndrome’s unique pathophysiology when selecting treatments, avoiding sodium channel blockers that can paradoxically worsen seizures. Families should understand that emerging targeted therapies, including established cannabinoid medications, offer more rational approaches than traditional trial-and-error antiepileptic protocols. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Ameliorating%20Seizures%20in%20Dravet%20Syndrome%3A%20A%20Review%20of%20Newly%20Approved%20and%20Investi...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41712149/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41712149/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Ameliorating%20Seizures%20in%20Dravet%20Syndrome%3A%20A%20Review%20of%20Newly%20Approved%20and%20Investi...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41712149/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41712149/](https://pubmed.ncbi.nlm.nih.gov/41712149/) Table of Contents - [FAQ](#FAQ)[What is Dravet syndrome and how common is it?](#What_is_Dravet_syndrome_and_how_common_is_it) - [How effective is CBD in treating Dravet syndrome seizures?](#How_effective_is_CBD_in_treating_Dravet_syndrome_seizures) - [What are the main treatment challenges in Dravet syndrome?](#What_are_the_main_treatment_challenges_in_Dravet_syndrome) - [Are there new therapeutic approaches being developed for Dravet syndrome?](#Are_there_new_therapeutic_approaches_being_developed_for_Dravet_syndrome) - [What is the prognosis for patients with Dravet syndrome?](#What_is_the_prognosis_for_patients_with_Dravet_syndrome) - [Related](#Related) ## FAQ #### What is Dravet syndrome and how common is it? Dravet syndrome is a severe form of infantile-onset epilepsy characterized by frequent drug-resistant seizures, cognitive and motor impairments, and increased risk of sudden unexpected death in epilepsy (SUDEP). Over 95% of cases are caused by loss-of-function mutations in the SCN1A gene, which encodes a critical voltage-gated sodium channel in the brain. #### How effective is CBD in treating Dravet syndrome seizures? [Clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) have demonstrated that pharmaceutical-grade CBD (cannabidiol) can significantly reduce seizure frequency in Dravet syndrome patients when added to existing antiepileptic treatments. The FDA has approved Epidiolex, a purified CBD formulation, specifically for treating seizures associated with Dravet syndrome based on robust [clinical evidence](https://cedclinic.com/academic-partnerships-cannabis-research/). #### What are the main treatment challenges in Dravet syndrome? Dravet syndrome is notoriously drug-resistant, meaning conventional antiepileptic medications often fail to adequately control seizures. This resistance to treatment, combined with the syndrome’s early onset and progressive nature, makes it one of the most challenging pediatric epilepsies to manage clinically. #### Are there new therapeutic approaches being developed for Dravet syndrome? Yes, the review discusses several emerging treatments including newly approved medications, investigational drugs, and cutting-edge RNA and gene-based therapies. These novel approaches aim to address the underlying genetic cause of Dravet syndrome rather than just managing symptoms. #### What is the prognosis for patients with Dravet syndrome? Dravet syndrome carries a serious prognosis with elevated risk of premature mortality, particularly from sudden unexpected death in epilepsy (SUDEP). Patients typically experience ongoing cognitive and motor impairments throughout their lives, making early diagnosis and aggressive treatment crucial for optimizing outcomes. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Ameliorating Seizures in Dravet Syndrome: A Review of Newly Approved and Investigational Drugs, RNA and Gene-Based Therapies.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41712149/”, “about”: “cns drugs [clinical study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) ameliorating seizures”, “isPartOf”: “CNS drugs”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).](https://cedclinic.com/transdermal-cannabidiol-gel-children-inspire-trial/) This trial explores cannabidiol gel's safety and efficacy in pediatric neurological conditions, relevant to cannabinoid therapies in epilepsy. [Learn More](https://cedclinic.com/transdermal-cannabidiol-gel-children-inspire-trial/) [FDA-Approved CBD Drug Shows Early Promise in Anorexia Patients](https://cedclinic.com/fda-approved-cbd-drug-anorexia-promise/) Examines the therapeutic potential of FDA-approved CBD drugs, highlighting their expanding role in neurological and systemic disorders. [Read Article](https://cedclinic.com/fda-approved-cbd-drug-anorexia-promise/) [Cannabis Compound Shows Promise in Fighting Alzheimer's by Calming Brain Inflammation](https://cedclinic.com/cannabis-compounds-alzheimers-brain-inflammation/) Discusses cannabis compounds' neuroprotective effects, providing insight into their potential in treating neurological diseases. [Explore Insights](https://cedclinic.com/cannabis-compounds-alzheimers-brain-inflammation/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).